Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Boron containing doai
Patent
1993-09-10
1996-02-20
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Boron containing doai
514 23, A61K 3169
Patent
active
054929008
ABSTRACT:
A process and product formulated by complexing d,1- or 1-p-boronophenylalanine (BPA) with a saccharide in an aqueous solution formation of the complex being facilitated by raising the pH of this solution to a higher pH of about 10 or lowering the pH of the solution to a lower pH of about 2 and then readjusting the pH to a body physiological pH of about 7.4. This BPA saccharide complex can then be delivered by i.v. or other injection or administered orally as a key component of the BNCT cancer treatment process. The pH manipulation causes a much higher solubility of BPA and thus a higher boron concentration in the tumor, thereby improving the therapy.
REFERENCES:
patent: 4824659 (1989-04-01), Hawthorne
patent: 5021572 (1991-06-01), Gabel
patent: 5116980 (1992-05-01), Gabel
patent: 5144026 (1992-09-01), Gabel
patent: 5149801 (1992-09-01), Kahl et al.
patent: 5157149 (1992-10-01), Samsel
LaHann, Lu et al. Advances in Neutron Capture Therapy, Barth and Soloway, eds.i pp. 585-589, presented Sep. 14-17, 1992, Fifth International Symposium on Neutron Capture Therapy, Columbus, Ohio.
LaHann, Sills et al. Advances in Neutron Capture Therapy, Barth and Soloway, eds.; pp. 513-517, presented Sep. 14-17, 1992, Fifth International Symposium on Neutron Capture Therapy, Columbus, Ohio.
Barth, et al., Boron Neutron Capture Therapy for Cancer, Dec. 15, 1992, vol. 70, No. 12, pp. 2995-3007.
Soloway, et al., Evaluation of Boron Compounds for use in Neutron Capture Therapy of Brain Tumors. I. Animal Investigations, Mar. 10, 1961, vol. 134, pp. 117-122. J. Pharmacol. Exp. Therapeutics.
Mori, et al., Complex Formation of p-Boronophenylalanine With Some Monosaccharides, 1989, pp. 273-277.
Yoshino, et al., Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides, 1989, pp. 127-129.
Coderre, et al., Selective Targeting of Boronophenylalanine to Melanoma in BALB/c Mice for Neutron Capture Therapy, Sep. 10, 1987, pp. 6377-6383.
Coderre, et al., Selective Delivery of Boron by the Melanin Precursor Analogue p-Boronophenylalanine to Tumors Others Than Melanoma, Oct. 2, 1989, pp. 138-141.
Mishima, et al., New Thermal Neutron Capture Therapy for Malignant Melanoma: Melanogenesis-Seeking .sup.10 B Molecule-Melanoma Cell Interaction From In Vitro to First Clinical Trial, Sep. 21, 1988, pp. 226-234.
Fonda Kathleen Kahler
Neutron Technology Corporation
Pedersen Barbara S.
Pedersen Ken J.
Robinson Douglas W.
LandOfFree
Method for enhancing the solubility of the boron delivery drug, does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhancing the solubility of the boron delivery drug, , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing the solubility of the boron delivery drug, will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1355965